Vice President, Clinical Pharmacology

Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner. These distinctive capabilities enable AP3's direct application for drug design optimization for monotherapy activity, the identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon's drug candidates.

Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon's ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third-party Phase 2 trials in patients with ovarian cancer treated with ACR-368. The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its co-crystallography-driven, internally discovered preclinical stage pipeline programs. These include ACR-2316, a potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity as demonstrated in preclinical studies against benchmark inhibitors, and a cell cycle program with an undisclosed target.

Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.

Position Overview:

We are seeking a dynamic and strategic Vice President of Clinical Pharmacology to lead our Pharmacology efforts. The successful candidate will play a crucial role in advancing our therapeutic pipeline, overseeing the strategic planning and execution of pharmacology studies that support the clinical development of new drug candidates. This position will report to the Chief Development Officer and will collaborate closely with the Chief Medical Officer and other executive leadership members to align pharmacological strategies with overall corporate goals. This position will be based in Watertown, MA.

Duties and Responsibilities:

• Closely participate in the design, implementation, and interpretation of pharmacological studies, ensuring robust methodology and compliance with regulatory standards.

• Lead pharmacokinetic and pharmacology analyses at the clinical development stage.

• Participate in the advancement of drug candidates from preclinical development, ensuring seamless transitions into clinical trials.

• Support the clinical dose strategy and selection process through analysis of preclinical and early clinical studies.

• Collaborate with cross-functional teams, including research and development, clinical development, regulatory affairs, and program management, to define and implement successful development strategies.

• Provide expert pharmacological insight into the validation of pharmacokinetic and pharmacodynamic of therapeutic candidates.

• Serve as a key scientific spokesperson for the company, comfortable presenting pharmacology data with authority at internal meetings, medical/scientific conferences, and with corporate partners.

• Ensure scientific excellence and integrity in all pharmacological data published or communicated to regulatory bodies.

Qualifications include:

• Pharm D and/or PhD in Clinical Pharmacology or Biochemistry.

• At least 10 years of experience in oncology clinical pharmacology, with a significant track record in clinical drug development in an industry setting.

• Solid understanding of clinical objectives, constraints and risks in drug safety and efficacy

• Proven leadership experience with the ability to successfully manage cross functional relations.

• Strong knowledge of the drug development process, particularly in oncology, including IND/NDA enabling studies.

• Excellent strategic thinking and problem-solving skills.

• Demonstrated ability to work effectively in a collaborative, fast-paced team environment.

• Strong communication and interpersonal skills, proficient in presenting scientific data and strategies to stakeholders including non-scientific audiences.

Acrivon Therapeutics is proud to be an equal opportunity employer and to provide equal opportunities to all employees and applicants for employment without regard to race, color, religion, sex or gender identity, national origin, age, disability, sexual orientation or genetics. In addition to federal law requirements, Acrivon Therapeutics complies with applicable state and local laws governing nondiscrimination in employment.